Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant ADT and 18F-Flotufolastat PSMA PET/CT in High-Risk Localized Prostate Cancer
NCT07455903Phase 2Recruiting
- Sponsor
- Baptist Health South Florida
- Start
- Jul 2026
- Primary completion
- Feb 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of flotufolastat f 18 in prostate cancer (PCa), sponsored by Baptist Health South Florida. Primary endpoints: Objective response rate based on PSMA PET at 6 months and Objective response rate based on Response Evaluation Criteria in PSMA Imaging (RECIP 1.0) at 6 months. Started Jul 2026; status: recruiting.
02
Drugs
flotufolastat f 18
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07455903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07455903.